Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
11.90
-0.06 (-0.50%)
Jul 24, 2025, 10:14 AM - Market open

Company Description

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.

The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension.

The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA.

Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Ocular Therapeutix, Inc.
Ocular Therapeutix logo
CountryUnited States
Founded2006
IPO DateJul 25, 2014
IndustryBiotechnology
SectorHealthcare
Employees274
CEOPravin Dugel

Contact Details

Address:
15 Crosby Drive
Bedford, Massachusetts 01730
United States
Phone781 357 4000
Websiteocutx.com

Stock Details

Ticker SymbolOCUL
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001393434
CUSIP Number67576A100
ISIN NumberUS67576A1007
SIC Code2834

Key Executives

NamePosition
Dr. Pravin U. Dugel M.D.Executive Chairman, President and Chief Executive Officer
Dr. Jeffrey S. Heier M.D.Chief Scientific Officer
Dr. Peter K. Kaiser M.D.Chief Development Officer
Donald Notman Jr.Chief Financial Officer, Chief Operating Officer and Principal Accounting Officer
Dr. Peter K. Jarrett Ph.D.Chief Technical Officer
William S. Slattery Jr.Vice President of Investor Relations
Todd D.C. Anderman J.D.Chief Legal Officer and Corporate Secretary
William H. Ransone IIVice President of Global Sales and Marketing
Barry Rubenstein M.S.Chief Human Resources Officer
Steve MeyersChief Commercial Officer

Latest SEC Filings

DateTypeTitle
Jul 8, 2025SCHEDULE 13GFiling
Jun 11, 2025S-8Securities to be offered to employees in employee benefit plans
Jun 11, 20258-KCurrent Report
Jun 2, 2025144Filing
May 23, 2025144Filing
May 23, 2025144Filing
May 23, 2025144Filing
May 23, 2025144Filing
May 15, 2025SCHEDULE 13G/AFiling
May 5, 202510-QQuarterly Report